TechGuru, We need to monetize an indication (stre

TechGuru,

Quote:

---

We need to monetize an indication (strengthen our financials) and then go full blast with the others.

---

I try to dig below headlines to gain a better understanding of new directions a company might be heading into.

On the last call Dr. Paterson said:

Quote:

---

“What we've learned through COVID is going to be incredibly beneficial for CytoDyn going forward in terms of ADDITIONAL indications (his emphasis -- not mine) and because of the broad effects that we see on the immune system.”

---

CytoDyn’s SEC filings have, for some time, contained the following language:

Quote:

---

“Some disease processes that we believe could benefit from CCR5 blockade include many types of common cancers, GvHD (a reaction occurring in some patients after bone marrow transplantation), NASH, autoimmunity and chronic inflammation, such as rheumatoid arthritis and psoriasis.”

---

And today, CytoDyn announced the appointment of Samir Patel, M.D., to its Board of Directors. And his credentials include:

Quote:

---

“Previously he was Medical Director at Centocor, Inc., (now Janssen Biotech, Inc.) a Johnson & Johnson Company. Dr. Patel is board certified in rheumatology and was in medical practice in Austin, Texas. He has published several papers from his clinical research studies. Dr. Patel received his BS in Biology from University of Cincinnati, Doctor of Medicine from Medical College of Ohio, and completed his internal medicine internship and residency, as well as rheumatology fellowship at University of New Mexico School of Medicine Affiliated Hospitals.”

---

It's early days, but I like this appointment -- and I think it bodes well for the company’s exploration of some new high-dollar value indication targets.